lesinurad
Commercial- Indications
- Gout, Hyperuricemia
Company intelligence / Profile preview
Ardea Biosciences, Inc.
San Diego, California, United Statesastrazeneca.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Ardea Biosciences developed lesinurad (RDEA594), a selective URAT1 inhibitor for gout treatment that reached Phase 3 clinical trials. In Phase 2 trials, lesinurad showed response rates between 70-80% compared to 28% for placebo.
- Therapeutic areas
- Metabolic DisordersRheumatologyImmunologyOncologyInfectious Diseases
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Bayer HealthCare (for BAY 86-9766/RDEA119)
Beyond the preview
Go deeper on Ardea Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ardea Biosciences, Inc..